158 related articles for article (PubMed ID: 25681308)
21. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?
Kocar M; Bozkurtlar E; Telli F; Yumuk F; Kaya H; Kocar H; Serdar Turhal N
J BUON; 2014; 19(1):245-9. PubMed ID: 24659671
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Rigakos G; Razis E; Koliou GA; Oikonomopoulos G; Tsolaki E; Sperinde J; Chrisafi S; Zarkavelis G; Pazarli E; Batistatou A; Kourea HP; Papakostas P; Bafaloukos D; Asimakopoulou NI; Res E; Kotsakis A; Pectasides D; Koutras A; Christodoulou C; Fountzilas G
Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
Hackshaw MD; Danysh HE; Henderson M; Wang E; Tu N; Islam Z; Ladner A; Ritchey ME; Salas M
BMC Cancer; 2021 Aug; 21(1):967. PubMed ID: 34454469
[TBL] [Abstract][Full Text] [Related]
25. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
26. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
Duchnowska R; Dziadziuszko R; Czartoryska-Arłukowicz B; Radecka B; Szostakiewicz B; Sosińska-Mielcarek K; Karpińska A; Starosławska E; Kubiatowski T; Szczylik C
Breast Cancer Res Treat; 2009 Sep; 117(2):297-303. PubMed ID: 19130219
[TBL] [Abstract][Full Text] [Related]
29. Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients.
Kaplan MA; Inal A; Kucukoner M; Urakci Z; Ekici F; Firat U; Zincircioglu SB; Isikdogan A
Onkologie; 2013; 36(4):176-81. PubMed ID: 23548965
[TBL] [Abstract][Full Text] [Related]
30. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
31. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
[TBL] [Abstract][Full Text] [Related]
32. Letter to the editor. Women with HER2-positive metastatic breast cancer have significantly longer survival after diagnosis of brain metastasis(BM) than those with HER2-negative disease.
Kilickap S; Arslan C
Am J Clin Oncol; 2009 Apr; 32(2):226. PubMed ID: 19346820
[No Abstract] [Full Text] [Related]
33. Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.
Paluch-Shimon S; Ben-Baruch N; Wolf I; Zach L; Kopolovic J; Kruglikova A; Modiano T; Yosepovich A; Catane R; Kaufman B
Am J Clin Oncol; 2009 Oct; 32(5):504-8. PubMed ID: 19564785
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
37. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor is Expressed in Breast Cancer Brain Metastases.
Bergen ES; Berghoff AS; Steindl A; Rajky O; Mercea PA; Kiesel B; Tendl-Schulz K; Bago-Horvath Z; Exner R; Fitzal F; Dieckmann K; Widhalm G; Steger GG; Preusser M; Bartsch R
Appl Immunohistochem Mol Morphol; 2021 Nov-Dec 01; 29(10):728-733. PubMed ID: 34121071
[TBL] [Abstract][Full Text] [Related]
39. Subtype switching in breast cancer brain metastases: a multicenter analysis.
Hulsbergen AFC; Claes A; Kavouridis VK; Ansaripour A; Nogarede C; Hughes ME; Smith TR; Brastianos PK; Verhoeff JJC; Lin NU; Broekman MLD
Neuro Oncol; 2020 Aug; 22(8):1173-1181. PubMed ID: 31970416
[TBL] [Abstract][Full Text] [Related]
40. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
